Drug Profile
NGP 555
Alternative Names: NGP-555; NGX-555Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator TorreyPines Therapeutics Inc
- Developer NeuroGenetic Pharmaceuticals
- Class Amines; Antidementias; Fluorine compounds; Imidazoles; Small molecules; Thiazoles
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (PO, Capsule)
- 09 Jan 2017 NeuroGenetic Pharmaceuticals completes a phase Ib trial in healthy volunteers in USA
- 01 Jan 2016 NeuroGenetic Pharmaceuticals initiates enrolment in a phase Ib trial in healthy volunteers in USA (NCT02537938)